275 related articles for article (PubMed ID: 12089226)
21. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
[TBL] [Abstract][Full Text] [Related]
22. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Park JH; Lee JL
Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.
Millikan RE; Plunkett WK; Smith TL; Williams DL; Logothetis CJ
Cancer; 2001 Jul; 92(1):194-9. PubMed ID: 11443627
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
[TBL] [Abstract][Full Text] [Related]
25. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
Theodore C; Bidault F; Bouvet-Forteau N; Abdelatif M; Fizazi K; di Palma M; Wibault P; de Crevoisier R; Laplanche A
Ann Oncol; 2006 Jun; 17(6):990-4. PubMed ID: 16600984
[TBL] [Abstract][Full Text] [Related]
26. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin for Kidney Transplant Patients With Locally Advanced Transitional Cell Carcinoma: A Single-center Experience.
Wang ZP; Wang WY; Zhu YC; Xiao J; Lin J; Guo YW; Tian Y
Transplant Proc; 2016; 48(6):2076-9. PubMed ID: 27569947
[TBL] [Abstract][Full Text] [Related]
28. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Lara PN; Meyers FJ; Law LY; Dawson NA; Houston J; Lauder I; Edelman MJ
Cancer; 2004 Jan; 100(1):82-8. PubMed ID: 14692027
[TBL] [Abstract][Full Text] [Related]
29. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G;
Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
34. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
[TBL] [Abstract][Full Text] [Related]
36. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
Bourgeois H; Billiart I; Chabrun V; Chieze S; Lemerre D; Germain T; Ferrand V; Meurice JC; Daban A; Tourani JM
Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
[TBL] [Abstract][Full Text] [Related]
37. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
38. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.
Sweeney CJ; Williams SD; Finch DE; Bihrle R; Foster RS; Collins M; Fox S; Roth BJ
Cancer; 1999 Aug; 86(3):514-8. PubMed ID: 10430261
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
[TBL] [Abstract][Full Text] [Related]
40. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Baka S; Manegold C; Buchholz E; Schott-von-Römer K; Lorigan P; Nagel S; Blackhall F; Aschroft L; Thatcher N
Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]